Navigating CAR T-cell Therapy in R/R ALL: Expert Perspectives

Author(s):

Elias Jabbour, MDEvandro D. Bezerra, MD

The panel examines the current positioning of CAR T-cell therapy within the treatment paradigm for Relapsed / Refractory Acute Lymphoblastic Leukemia, considering the distinctions between Philadelphia chromosome-positive and negative patients.

EP: 1.Overview of CAR T-cell Therapies in R/R B-cell ALL

EP: 2.CAR T-cell Therapy: Mechanisms of Actions of Brexucabtagene Autoleucel and Obecabtagene Autoleucel

EP: 3.Considerations for Dosing and Lymphodepletion with CAR T-cell Therapy in R/R ALL

EP: 4.Expert Perspectives on CAR T-Cell Therapy Logistics: Collection to Treatment

EP: 5.Overview of Available Treatment Options in R/R B-cell ALL

Now Viewing

EP: 6.Navigating CAR T-cell Therapy in R/R ALL: Expert Perspectives

EP: 7.Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data

EP: 8.Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL

EP: 9.Expert Perspectives on Bridging Therapy Strategies Prior to CAR T-cell Therapy

EP: 10.Sequencing Strategies with CAR T-cell Therapy in Patients with or without Prior Blinatumomab Treatment

EP: 11.Translating Data Updates from FELIX and ZUMA-3 to the Clinical Practice Setting

EP: 12.Expert Perspectives on the Potential Impact of Obe-cel on the Treatment Landscape for R/R ALL

EP: 13.Treatment Approaches with Consolidation and Maintenance Post CAR T-cell Therapy

EP: 14.Future Perspectives on CAR T-cell Therapy in R/R B-cell ALL

EP: 15.Frequency, Correlation with Clinical Outcomes, and Risk Factors for Severe CRS and ICANS in CAR T-cell Therapy

EP: 16.Expert Perspectives in Monitoring and Management Strategies for CRS, ICANS, and Other Long-Term Toxicities Associated with CAR T-cell Therapy

EP: 17.Logistical and Access Challenges with CAR T-cell Therapy in R/R ALL

EP: 18.Strategies and Resources for Overcoming Barriers to CAR T-Cell Therapy

EP: 19.Role of Multidisciplinary Team & Logistics of CAR T-cell Therapy Administration in the Inpatient or Outpatient Setting

EP: 20.Key Takeaways and Clinical Pearls in the Treatment of R/R ALL

Video content above is prompted by the following:

Where does CAR T-cell therapy currently fall in your treatment paradigm?
- Does it differ between patients who are Philadelphia positive vs. negative, or those with high-risk features, or extramedullary disease?
How does bulk of disease or percentage of blasts factor into your decision making?